Stem Cells International
Volume 2016 (2016), Article ID 9378081, 18 pages
http://dx.doi.org/10.1155/2016/9378081

Research Article

Characterization of Cellular and Molecular Heterogeneity of Bone Marrow Stromal Cells

Mona Elsafadi,1,2 Muthurangan Manikandan,¹ Muhammad Atteya,1,3 Jamil Amjad Hashmi,⁴ Zafar Iqbal,⁵ Abdullah Aldahmash,1,6 Musaad Alfayez,¹ Moustapha Kassem,1,2 and Amer Mahmood1,2

¹Stem Cell Unit, Department of Anatomy, College of Medicine, King Saud University, Riyadh, Saudi Arabia
²Molecular Endocrinology Laboratory (KMEB), Department of Endocrinology, University of Southern Denmark, Odense, Denmark
³Department of Histology, Faculty of Medicine, Cairo University, Egypt
⁴Center for Genetics and Inherited Diseases, Taibah University, Al-Madina Al-Munawara, Saudi Arabia
⁵College of Applied Medical Sciences, King Saud Bin Abdulaziz University for Health Sciences (KSAU-HS), National Guards Health Affairs, Riyadh, Saudi Arabia
⁶Prince Naïf Health and Research Center, College of Medicine, King Saud University, Riyadh, Saudi Arabia

Received 14 April 2016; Accepted 26 May 2016

Academic Editor: Giorgio Mori

Copyright © 2016 Mona Elsafadi et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract.

Human bone marrow-derived stromal stem cells (hBMSC) exhibit multiple functions, including differentiation into skeletal cells (progenitor function), hematopoiesis support, and immune regulation (nonprogenitor function). We have previously demonstrated the presence of morphological and functional heterogeneity of hBMSC cultures. In the present study, we characterized in detail two hTERT-BMSC clonal cell populations termed here CL1 and CL2 that represent an opposing phenotype with respect to morphology, markers expression: alkaline phosphatase (ALP) and CD146, and ex vivo differentiation potential. CL1 differentiated readily to osteoblasts, adipocytes, and chondrocytes as shown by expression of lineage specific genes and proteins. Whole genome transcriptome profiling of CL1 versus CL2 revealed enrichment in CL1 of bone-, mineralization-, and skeletal muscle-related genes, for example, ALP, POSTN, IGFBP5 BMP4, and CXCL12. On the other hand, CL2 transcriptome was enriched in immune modulatory genes, for example, CD14, CD99, NOTCH3, CXCL6, CFB, and CFI. Furthermore, gene expression microarray analysis of osteoblast differentiated CL1 versus CL2 showed significant upregulation in CL1 of bone development and osteoblast differentiation genes which included several homeobox genes: TBX15, HOXA2 and HOXA10, and IGF1, FGFR3, BMP6, MCAM, ITGA10, IGFBP5, and ALP. siRNA-based downregulation of the ALP gene in CL1 impaired osteoblastic and adipocytic differentiation. Our studies demonstrate the existence of molecular and functional heterogeneity in cultured hBMSC. ALP can be employed to identify osteoblastic and adipocytic progenitor cells in the heterogeneous hBMSC cultures.

1. Introduction

Human bone marrow stromal (also known as skeletal or mesenchymal) stem cells (hBMSC) are increasingly employed in clinical trials for enhancing tissue regeneration following injury [1]. Typically, hBMSC are isolated by their ability to adhere to the plastic surfaces of in vitro culture plates. However, the cultured hBMSC exhibit morphological heterogeneity suggesting the presence of functional heterogeneity [2, 3]. It has also been suggested that the use of heterogeneous cell populations in clinical trials of hBMSC-based therapies caused variability in the observed treatment effects [4]. Thus, for the efficient use of hBMSC in therapy, better cellular and molecular characterization of hBMSC is required [1, 4].

There exist no specific markers that define the hBMSC phenotype. The plastic-adherent hBMSC are defined by the presence of surface expression of some CD surface markers with variable sensitivity and specificity [1]. Single cell clonal analysis revealed that only 25% of the cells are true stem cells based on their ability to differentiate into osteoblasts, adipocytes, and chondrocytes (trilineage differentiation) and to form heterotopic bone and bone marrow organ when implanted in vivo subcutaneously in immune deficient mice [5]. The identity of the remaining cells is not clarified, but they may represent lineage-committed cells [3]. Therefore, it is plausible that functional heterogeneity exists in cultured hBMSC, reflecting the in vivo functional and developmental heterogeneity of hBMSC [6].

In addition to their ability to differentiate into skeletal tissue cells (known as progenitor function), hBMSC possess immunomodulatory characteristics (known as nonprogenitor functions) [7]. It is not clear whether these different functions are mediated by a number of independent subpopulations within the hBMSC [2]. Only a few studies have tried to identify the subpopulation within cultured hBMSC based on surface markers, for example, STRO1 and alkaline phosphatase (ALP), but limited molecular phenotyping has been conducted [8].

We have previously demonstrated the presence of morphological and functional heterogeneity of clones isolated from telomerized hMSC (hMSC-TERT) cell line [3]. The aim of the present study was therefore to further study in detail the heterogeneity of cultured hBMSC as demonstrated by two clonal cell lines with opposite cellular and functional phenotype. We also employed the DNA microarrays to define their molecular signature and signaling pathways associated with their functional phenotype.

2. Experimental Procedures

2.1. Cell Culture

As a model for hBMSC, we employed immortalized hBMSC-TERT cell line that is created from normal human BMSC by overexpression of human telomerase reverse transcriptase gene (hTERT) [9]. The hBMSC-TERT cells have been extensively characterized, and they exhibit similar cellular and molecular phenotype to primary MSC [10]. CL1 and CL2 cells are clonal cell populations of hBMSC-TERT identified in long term culture (passage numbers 15–25) of hBMSC-TERT and were chosen based on their distinct and different morphologies. Cells were cultured in Dulbecco’s Modified Eagle Medium (DMEM) supplemented with D-glucose 4500 mg/L, 4 mM L-glutamine and 110 mg/L sodium pyruvate, 10% Fetal Bovine Serum (FBS), 1x penicillin-streptomycin (Pen-strep), and nonessential amino acids (all purchased from Gibco-Invitrogen, USA). For some control experiments, primary bone marrow derived MSC (phBMSC) were employed. Sixty milliliters of bone marrow was aspirated from the iliac crest bone of consenting healthy donors. This procedure was approved by the King Khalid University Hospital-King Saud University ethics committee. phBMSC were isolated from bone marrow mononuclear cells by plastic adherence as described previously [9].

2.2. Cell Proliferation

Cell proliferation rate was determined by counting cell number and calculating population doubling (PD) rate. The cells were cultured in 25 cm² tissue culture Petri dish at cell density 0.5 × 10⁶ cells (28000 cells/cm²). At confluence, the cells were trypsinized and counted manually by hemocytometer. At each passage, population doubling was determined by the following formula: , where is the number of cells at confluence divided by the initial cell number. Cumulative PD level is the sum of population doublings, and PD rate is PD/time in culture.

2.3. Flow Cytometry

Cells were trypsinized to a single cell suspension, were recovered by centrifugation at 200 g for 5 min, washed twice in ice-cold PBS supplemented with 2% BSA, and resuspended at a concentration of 10⁵ cells/antibody. After incubation with the preconjugated antibodies, or matched isotype controls, for 30 min on ice in the dark, cells were washed with PBS, resuspended in 500 μL of PBS, and analyzed in the BD FACSCalibur flow cytometer (BD Biosciences). Living cells were gated in a dot plot of forward versus side scatter signals acquired on a linear scale. At least 10,000 gated events were acquired on a log fluorescence scale. Positive staining was distinct as the emission of a fluorescence signal that surpassed levels achieved by >99% of control cell population stained with corresponding isotype antibodies. The ratios of fluorescence signals versus scatter signals were calculated, and histograms were generated using the software Cell Quest Pro Software Version 3.3 (BD Biosciences). The following antibodies were used all from BD Biosciences: FITC-PE-APC-Mouse IgG1k isotype control, APC-Mouse Anti-Human CD44 (#559942), FITC-Mouse Anti-Human CD63 (#557305), PE-Mouse Anti-Human CD73 (#550257), PE-Mouse Anti-Human CD105 (#560839), PE-Mouse Anti-Human CD146 (#550315), PE-Mouse Anti-Human CD166 (#560903), and Alexa Fluor® 488 Mouse Anti-Human Alkaline Phosphatase (#561495).

2.4. Electron Microscopy

After trypsinizing the hBMSC cells from the flasks or 6-well plates were collected, the samples were washed with PBS, and the pellets were resuspended directly in 2.5% glutaraldehyde in 0.1 M phosphate buffer (pH 7.2), and kept at 4°C for 4 hr. First, the cells were washed with 0.1 M phosphate buffer (pH 7.2) and transferred to 1% osmium tetroxide (OsO4) solution in 0.1 M phosphate buffer (pH 7.2) for two hr. The cells were dehydrated in ascending grades of ethanol. The cells were then resuspended in acetone and were aliquoted into BEEM embedding capsules and infiltrated with acetone: resin mixture followed by embedding in a pure resin mixture for two hr. Semithin sections (0.5 μm thickness) and ultrathin sections (70 nm thickness) were prepared, examined, and photographed under a transmission electron microscope (TEM) (Jeol 1010, Jeol, Tokyo, Japan).

2.5. In Vitro Osteoblast Differentiation

Cells were grown in standard DMEM growth medium in 6-well plates at 20,000 cell/cm². When 70–80% confluence was achieved, test cells were cultured in DMEM supplemented with osteoblastic induction mixture (referred to as OS) containing 10% FBS, 1% Pen-strep, 50 μg/mL L-ascorbic acid (Wako Chemicals, Neuss, Germany), 10 mM β-glycerophosphate (Sigma) and 10 nM calcitriol (1α,25-dihydroxyvitamin D3; Sigma), and 10 nM dexamethasone (Sigma); noninduced cells (referred to as Cont) were cultured in normal growth media for the same duration as induced. The media were replaced three times per week. Cells cultured in standard culture medium were considered as control. At day 14 of differentiation, mineralized nodules became apparent and were stained with Alizarin Red S and ALP.

2.6. In Vitro Adipocyte Differentiation

Cells were grown in standard DMEM growth medium in 6-well plates at 0.3 × 10⁶ cells/mL. At 90–100% confluence, cells were cultured in DMEM supplemented with adipogenic (Adip) induction mixture containing 10% FBS, 10% Horse Serum (Sigma), 1% Pen-strep, 100 nM dexamethasone, 0.45 mM isobutyl methylxanthine (Sigma), 3 μg/mL insulin (Sigma), and 1 μM Rosiglitazone (Novo Nordisk, Bagsvaerd, Denmark). The media were replaced three times per week. Cells cultured in standard culture medium were considered as control. From day 3 of differentiation, small lipid droplets became visible and at day 7 they were stained with Oil Red-O and Nile red.

2.7. In Vitro Chondrogenic Differentiation

Both CL1 and CL2 cells were trypsinized and counted, around 1 × 10⁶ cells taken in each 15 mL conical tube centrifuged at 400 ×g for 5 minutes. For chondrocyte differentiation pellet culture system used, chondrocyte induction was done in media containing advanced DMEM/F12 supplemented with 1% ITS Premix Tissue Culture Supplement, 100 nM dexamethasone, Glutamax, and 10 ng/mL transforming growth factor-beta-3 (TGFβ-3). Cells were maintained in chondrocyte differentiation media for 21 days and changed every two days.

2.8. Cytochemical Staining

2.8.1. Alkaline Phosphatase (ALP) Staining

CL1 and CL2 cells were stained before OS differentiation for the basal ALP expression and after OB differentiation at day 7 of induction. Cells cultured in 6-well plates were washed in PBS −/− (-Ca, -Mg) and fixed in acetone/citrate buffer 10 mM at pH 4.2 for 5 min at room temperature. The Naphthol/Fast Red stain [0.2 mg/mL Naphthol AS-TR phosphate substrate (Sigma)] [0.417 mg/mL of Fast Red (Sigma)] was added for one hour at room temperature.

Histological tissue blocks were sectioned at 4 microns. Immunohistochemical staining was performed on CL1 and CL2 chondrocyte 3D pellets using DAKO EnVision and PowerVision according to the manufacturer’s instructions (DAKO, Glostrup, Denmark). Briefly, paraffin sections were incubated for 1 hour at room temperature with primary antibodies diluted in ChemMate (DAKO) (Human Anti-Col-10 and Human Anti-Col-2 ABI). Sections were washed subsequently in Tris-buffered saline (TBS, 0.05 M, pH 7.4), incubated for 30 minutes with secondary anti-mouse Ig/HRP-conjugated polymers (K4001, En Visionþ, DAKO), and visualized with 3,30-diaminobenzidine tetrahydrochloride (DAB, S3000, DAKO) or with 3-amino-9-ethylcarbazole (AEC, DAKO) according to manufacturer’s instruction. Controls were performed with nonimmune immunoglobulins of the same isotype as the primary antibodies (negative controls) and processed under identical conditions. Alcian blue staining was used to detect chondrocytes. Sections of paraffin-embedded implants were stained with Alcian blue (Sigma) solution, pH 2.5; at this pH all the glycoproteins (neutral and acidic) will be stained blue.

2.9. Alizarin Red S Staining for Mineralized Matrix

Seven-day-old OS differentiated cells in 6-well plates were used for Alizarin Red S staining. The cell layer was washed with PBS and then fixed with 70% ice-cold ethanol for 1 hr at −20°C. After removing the ethanol, the cell layer was rinsed with distilled water and stained with 40 nM AR-S (Sigma) pH 4.2 for 10 minutes at room temperature. Excess dye was washed off with water followed by a wash with PBS for few minutes to minimize nonspecific AR-S stain.

For quantifying the Alizarin Red S staining, the air-dried plates, the Alizarin Red S dye was eluted in 800 μL of acetic acid incubated in each well for 30 minutes at room temperature as described [11] and measured in spectrophotometer (BioTek, Epoch) at 405 nm.

2.10. Quantitative ALP Activity

To quantify ALP activity in CL1 and CL2 hBMSC before and after OS differentiation, we used the BioVision ALP activity colorimetric assay kit (BioVision, Inc, CA, USA) with some modifications. Cells were cultured in 96-well plates under normal conditions; then on day of analysis, wells were rinsed once with PBS and were fixed using 3.7% formaldehyde in 90% ethanol for 30 seconds at room temperature. Subsequently, fixative was removed, and 50 μL of pNPP solution was added to each well and incubated for 1 hour in the dark at room temperature. The reaction was subsequently stopped by adding 20 μL stop solution and gently shaking the plate. OD was then measured at 405 nm.

2.11. Oil Red-O Staining for Lipid Droplets

CL1 and CL2 cells differentiated to adipocytes with Adip induction media at day 7 were used. Accumulated cytoplasmic lipid droplets were visualized by staining with Oil Red-O. After washing cells grown in 6-well plates with PBS, the cells were fixed in 4% formaldehyde for 10 min at room temperature and then rinsed once with 3% isopropanol and stained for 1 hr at room temperature with filtered Oil Red-O staining solution (prepared by dissolving 0.5 g Oil Red-O powder in 60% isopropanol). To quantify staining of fat droplets, Oil Red-O was used as a stain. Oil Red-O was eluted by adding 100% isopropanol to each well, and color changes were measured by spectrophotometer at 510 nm (BioTek Spectrophotometer, Epoch).

2.12. Nile Red Fluorescence Determination and Quantification of Adipogenesis

A stock solution of Nile red (1 mg/mL) in DMSO was prepared and stored at −20°C protected from light. Staining was performed on unfixed cells. Cultured undifferentiated and day 7 adipocyte differentiated cells were grown in Corning polystyrene; flat bottom 96-well TC-treated black microplates (Corning, NY, USA) were washed once with PBS. The dye was then added directly to the cells (5 μg/mL in PBS), and the preparation was incubated for 10 min at room temperature and then washed twice with PBS. Fluorescent signal was measured using SpectraMax/M5 fluorescence spectrophotometer plate reader (Molecular Devices Co, Sunnyvale, CA, USA) using bottom well-scan mode where nine readings were taken per well using Ex (485 nm) and Em (572 nm) spectra.

2.13. Quantitative Real-Time PCR (qRT-PCR) Analysis

Total RNA was extracted using MagNA pure compact RNA isolation kit (Roche Applied Science, Germany, Cat number 04802993001) in an automated MagNA pure compact system (Roche, Germany) as recommended by the manufacturer. The total RNA was quantified by Nanodrop spectrophotometer (Nanodrop 2000, Thermo Scientific, USA). Complementary DNA (cDNA) was synthesized from 1 μg of the RNA samples using High Capacity cDNA Reverse Transcription kit (Applied Biosystems, USA) using Labnet, Multigene thermocycler according to the manufacturer’s instructions. Relative levels of mRNA were determined from cDNA by real-time PCR (Applied Biosystems-Real-Time PCR Detection System) with Power SYBR Green PCR kit (Applied Biosystems, UK) according to the manufacturer’s instructions. Following normalization to the reference gene GAPDH, quantification of gene expression was carried out using a comparative Ct method, where ΔCt is the difference between the CT values of the target and the reference gene, and fold induction was performed from the control (Cont) for the same time point. Primers (Supplementary Table  1 in Supplementary Material available online at http://dx.doi.org/10.1155/2016/9378081) were obtained from Applied Biosystems (USA) as TAQMAN primers, or previously published primers were used (see Supplementary Table  1).

2.14. DNA Microarray Global Gene Expression Analysis

Four hundred ng of total RNA was used as input for generating biotin-labeled cRNA (Ambion, Austin, TX, United States). cRNA samples were then hybridized onto Illumina® human-8 BeadChips version 3. Hybridization, washing, Cy3-streptavidin staining, and scanning were performed on the Illumina BeadStation 500 platform (Illumina, San Diego, CA, USA), according to the manufacturer’s instructions, and everything was done in triplicate. Expression data analysis was carried out using the Partek® genomic suite software. Raw data were background-subtracted, normalized using the “rank invariant” algorithm, and filtered for significant expression on the basis of negative control beads. Genes were considered significantly expressed with detection values ≤ 0.01. Differential expression analysis was performed with the Illumina custom method using freshly isolated primary hBMSC (used at passage 3) as a reference control. The following parameters were set to identify statistical significance: differential values ≤ 0.01; fold change ratio > 1.5. Pathway analysis was performed using DAVID Bioinformatics Resources 6.7 (http://david.abcc.ncifcrf.gov/) and GeneSpring GX software (Agilent Technologies). Pathway analysis for CL1 OS D14 versus CL2 OS D14 was conducted using the Single Experiment Pathway analysis feature in GeneSpring 12.0 (Agilent Technologies).

2.15. Small Interfering (si)RNA Transfection

For transfection, hBMSC in logarithmic growth phase were transfected with Silencer Select Predesigned ALP siRNA (25 nM) (Assay ID; s1298 and Cat number 4390824) (Ambion, The RNA Company, USA) using Lipofectamine RNAiMAX Reagent (Invitrogen, CA, USA) plus serum-free Opti-MEM®I medium under the conditions described by the manufacturer. At day 3 of transfection, the cells were induced for osteogenic differentiation for an additional 7 days. ALP staining was used as a control for the siRNA transfection efficiency and timeline.

2.16. Statistical Analysis

All of the results were presented as the mean and standard deviation (SD) of at least 3 independent experiments, with 3–5 technical repeats in each experiment. Student’s -test (two-tailed) was used for testing differences between groups. value <0.05 was considered statistically significant.

3. Results

3.1. Comparison between CL1 and CL2: Differences in Morphology, Proliferation, and Marker Expression Profile

We isolated two distinct clonal cell populations of hBMSC-TERT: hBMSC-CL1 and hBMSC-CL2 (for easiness will be termed hereafter CL1 and CL2) based on differences in cell morphology (Figure 1(a)). CL1 cells had cuboidal morphology whereas CL2 cells have spindle-shaped fibroblast-like morphology. CL1 cells had higher proliferation rate compared to CL2 (Figure 1(b)): mean PD rates of CL1 and CL2 were 0.714 and 0.429 PD/day, respectively (Figure 1(b)). Both CL1 and CL2 expressed surface marker profiles characteristics of hBMSC (>90%): CD44+, CD63+, CD73+, CD105+, and CD166+ (Figure 1(c)). However CL1 cells showed higher expression of CD146 (92.7% versus 12%) and ALP (98% versus 0%) compared to CL2 (Figure 1(d)). TEM revealed the presence of abundant pseudopodia in CL1 indicating high motility (Figure 1(e)(A)) as well as well-developed mitochondria and rough endoplasmic reticulum (rER) suggesting high metabolic activity. CL2 cells contained abundant phagocytic vacuole (pv), microvilli (mi), and lysosomes (ly) (Figure 1(e)).

(a)

(b)

(c)

(d)

(e)

(f)

Figure 1: Cellular phenotype of two clonal populations of human bone marrow stromal stem cells: CL1 and CL2. (a) Cell morphology. CL1 cells showed large cuboidal morphology while CL2 cells had spindle-shaped fibroblast-like morphology. (b) Growth curves showing population doubling (PD) rate during long term culture. (c) Flow cytometry analysis (FACS) shows expression of CD44, CD63, CD73, CD105, and CD166 in CL1 and CL2 cells. Matched isotype control was used for gating. (d) Flow cytometry analysis presented as dot blot of CD146 and alkaline phosphatase (ALP) cell surface proteins. (e) Transmission electron microscope (TEM). (A): CL1 (1200x); (B): CL2 (1500x). n: nucleus, nu: nucleolus, rER: rough endoplasmic reticulum, ly: lysosomes, pv: phagocytic vacuole, and rer: reticular stalk of rER. (f) Gene expression analysis using RT-PCR for a group of mesodermal and stromal genes. Gene expression was normalized to GAPDH and presented as fold change. Data is shown as mean ± SD of three independent experiments. ; .

We performed quantitative real-time PCR (RT-PCR) for genes expressed in mesodermal progenitor cells [12]. CL1 expressed higher levels of BMP4, MIXL1, WNT3a, and TWIST compared to CL2 (Figure 1(f), ). In contrast, CL2 expressed higher levels of Kinase Insert Domain Receptor (Type III Receptor Tyrosine Kinase) (KDR) expressed in endothelial cells and smooth muscle myosin heavy chain gene (smMHC) expressed in smooth muscle cells (Figure 1(f)).

3.2. CL1 Cells Exhibit Enhanced Osteoblast Differentiation

Following osteoblast (OB) differentiation induction, ALP staining and ALP enzymatic activity were significantly higher in CL1 compared to CL2 cells (Figure 2(a), ). Similarly, Alizarin Red staining and quantitation of formed mineralized matrix were more pronounced in CL1 cells (Figure 2(b), ). In addition, CL1 cells expressed higher levels of osteoblastic genes, ALP, RUNX2, and osteopontin (OPN) (Figure 2(c) upper panel) compared to CL2 cells.

(a)

(b)

(c)

(d)

(e)

Figure 2: In vitro osteoblastic and adipocytic differentiation of two clonal populations of human bone marrow stromal stem cells: CL1 and CL2 cells. Both cell lines were induced for osteoblast differentiation using standard protocol described in the Methods. (a) ALP staining at day 14 in control noninduced (Cont) and osteoblast induced cells (D14). Right panel shows ALP activity ( independent experiments, ). (b) Mineralized matrix formation visualized by Alizarin Red S staining. Right panel shows Alizarin Red quantification at day 14 and 21 after osteoblast differentiation ( independent experiments, ). (c) Quantitative RT-PCR of osteoblastic and adipocyte gene markers in CL1 and CL2 during osteoblast (upper panel) and adipocyte (lower panel) differentiation. ALP = alkaline phosphatase, OPN = osteopontin, LPL = lipoprotein lipase, and ADIPOQ = adiponectin. Data are presented as fold change in expression of each target gene normalized to GAPDH ( independent experiments, ;  ). (d) CL1 and CL2 lines were induced for adipocyte differentiation using standard protocol described in the Methods. Adipocyte formation was visualized at day 7 (Adip d7) and day 14 (Adip d14) by Oil Red-O staining. Lower panel presents quantification of Nile red staining ( independent experiments, ). (e) CL1 and CL2 lines were induced for chondrocyte differentiation using 21-day pellet culture method as described in the Methods. The pellets were stained with Alcian blue, collagen 10 (Col X), and collagen 2 (Col II) (original magnification 5x).

Global gene expression microarray analysis of OB differentiated cells at day 14 showed around 1060 genes significantly upregulated more than 2-fold () in CL1. Among the upregulated genes, 80 genes were annotated to bone development and osteoblast differentiation (Table 1). The highest upregulated genes included paired-like homeodomain 2 (PITX2), Insulin-like growth factor 1 (IGF1) and collagen, type V, alpha 3 (COL5A3), osteomodulin (OMD), and T-box 15 (TBX15) (Table 1). Furthermore, several known osteoblast-related genes were upregulated in CL1 cells such as bone morphogenetic protein 6 (BMP6), fibroblast growth factor receptor 3 (FGFR3), insulin-like growth factor binding protein 5 (IGFBP5), and vitamin D (1,25-dihydroxyvitamin D3) receptor (VDR) (Table 1). On the other hand, 1200 genes were upregulated in CL2 cells: 255 genes were annotated to immunity and immune response and defense. This category included genes from, complement system, chemokine (C-C motif) ligands, interferon family, chemokine (C-X-C motif) ligands, and receptor, major histocompatibility complex class II molecules, interleukins, and tumor necrosis factor receptor superfamily (Table 2 and Supplementary Table .

Table 1: Microarray data analysis showing genes related to bone development and osteoblast differentiation upregulated in CL1 versus CL2 cells.

Probe ID
Genbank accession
Gene name
Gene symbol
FC

A_23_P167367
NM_153426
Paired-like homeodomain 2
PITX2
308.84

A_23_P13907
NM_000618
Insulin-like growth factor 1 (somatomedin C)
IGF1
118.00

A_23_P55749
NM_015719
Collagen, type V, alpha 3
COL5A3
75.11

A_23_P94397
NM_005014
Osteomodulin
OMD
56.07

A_24_P128442
NM_152380
T-box 15
TBX15
54.38

A_33_P3708413
NM_003480
Microfibrillar associated protein 5
MFAP5
53.73

A_24_P72064
NM_000163
Growth hormone receptor
GHR
51.47

A_23_P215454
NM_001278939
Elastin
ELN
50.15

A_24_P200854
NM_006735
Homeobox A2
HOXA2
44.99

A_23_P19624
NM_001718
Bone morphogenetic protein 6
BMP6
41.43

A_23_P500501
NM_000142
Fibroblast growth factor receptor 3
FGFR3
33.95

A_23_P154605
NM_018837
Sulfatase 2
SULF2
29.57

A_23_P28815
NM_000782
Cytochrome P450, family 24, subfamily A, polypeptide 1
CYP24A1
22.47

A_23_P210109
NM_019885
Cytochrome P450, family 26, subfamily B, polypeptide 1
CYP26B1
22.42

A_23_P323180
NM_006898
Homeobox D3
HOXD3
21.08

A_32_P405759
NM_152888
Collagen, type XXII, alpha 1
COL22A1
20.36

A_33_P3363799
NM_001242607
Neural cell adhesion molecule 1
NCAM1
17.33

A_33_P3381378
NM_001257096
Paired box 1
PAX1
17.12

A_23_P383009
NM_000599
Insulin-like growth factor binding protein 5
IGFBP5
14.67

A_33_P3382856
NM_133507
Decorin
DCN
14.38

A_23_P10206
NM_005328
Hyaluronan synthase 2
HAS2
14.33

A_24_P77904
NM_018951
Homeobox A10
HOXA10
13.64

A_23_P2814
NM_005905
SMAD family member 9
SMAD9
12.45

A_23_P88404
NM_003239
Transforming growth factor, beta 3
TGFB3
12.11

A_32_P4595
NM_000337
Sarcoglycan, delta (35 kDa dystrophin-associated glycoprotein)
SGCD
8.95

A_23_P162171
NM_006500
Melanoma cell adhesion molecule
MCAM
8.60

A_24_P38276
NM_003505
Frizzled class receptor 1
FZD1
7.81

A_23_P24129
NM_012242
Dickkopf WNT signaling pathway inhibitor 1
DKK1
7.04

A_33_P3264528
NM_005523
Homeobox A11
HOXA11
6.64

A_33_P3220470
NM_005585
SMAD family member 6
SMAD6
6.47

A_23_P23783
NM_000261
Myocilin, trabecular meshwork inducible glucocorticoid response
MYOC
6.41

A_33_P3263432
NM_003637
Integrin, alpha 10
ITGA10
6.35

A_23_P383009
NM_000599
Insulin-like growth factor binding protein 5
IGFBP5
6.18

A_33_P3219090
NM_005542
Insulin induced gene 1
INSIG1
5.78

A_23_P162589
NM_001017535
Vitamin D (1,25-dihydroxyvitamin D3) receptor
VDR
5.68

A_23_P374695
NM_000459
TEK tyrosine kinase, endothelial
TEK
5.65

A_24_P261169
NM_006378
Sema domain, immunoglobulin domain (Ig), transmembrane domain (TM), and short cytoplasmic domain, (semaphorin) 4D
SEMA4D
5.41

A_33_P3297930
NM_005202
Collagen, type VIII, alpha 2
COL8A2
5.138

A_23_P206359
NM_004360
Cadherin 1, type 1, E-cadherin (epithelial)
CDH1
5.12

A_24_P264943
NM_000095
Cartilage oligomeric matrix protein
COMP
5.07

A_33_P3214948
NM_014767
Sparc/osteonectin, cwcv, and kazal-like domains proteoglycan (testican) 2
SPOCK2
4.54

A_24_P55496
NM_053001
Odd-skipped related transcription factor 2
OSR2
4.38

A_24_P354689
NM_004598
Sparc/osteonectin, cwcv, and kazal-like domains proteoglycan (testican) 1
SPOCK1
4.23

A_23_P69030
NM_001850
Collagen, type VIII, alpha 1
COL8A1
3.93

A_23_P128084
NM_002206
Integrin, alpha 7
ITGA7
3.91

A_24_P3249
NM_000965
Retinoic acid receptor, beta
RARB
3.91

A_24_P168574
AJ224867
GNAS complex locus
GNAS
3.83

A_23_P320739
NM_002397
Myocyte enhancer factor 2C
MEF2C
3.74

A_23_P429383
NM_014213
Homeobox D9
HOXD9
3.54

A_23_P42322
NM_080680
Collagen, type XI, alpha 2
COL11A2
3.42

A_23_P160318
NM_001856
Collagen, type XVI, alpha 1
COL16A1
3.36

A_33_P3407013
NM_000600
Interleukin 6
IL6
3.30

A_23_P315364
NM_002089
Chemokine (C-X-C motif) ligand 2
CXCL2
3.29

A_33_P3413168
BC007696
Collagen, type XXVII, alpha 1
COL27A1
3.08

A_23_P43164
NM_015170
Sulfatase 1
SULF1
3.05

A_23_P58676
NM_001204375
Natriuretic peptide receptor 3
NPR3
3.04

A_33_P3290562
NM_000168
GLI family zinc finger 3
GLI3
3.00

A_23_P69497
NM_003278
C-type lectin domain family 3, member B
CLEC3B
2.99

A_24_P353619
NM_000478
Alkaline phosphatase, liver/bone/kidney
ALPL
2.99

A_33_P3305749
NM_000965
Retinoic acid receptor, beta
RARB
2.89

A_23_P307328
NM_007331
Wolf-Hirschhorn syndrome candidate 1
WHSC1
2.77

A_23_P152305
NM_001797
Cadherin 11, type 2, OB-cadherin (osteoblast)
CDH11
2.77

A_23_P216361
NM_021110
Collagen, type XIV, alpha 1
COL14A1
2.62

A_23_P7313
NM_001040058
Secreted phosphoprotein 1
SPP1
2.60

A_24_P267592
NM_015474
SAM domain and HD domain 1
SAMHD1
2.54

A_23_P210482
NM_000022
Adenosine deaminase
ADA
2.52

A_23_P148047
NM_000958
Prostaglandin E receptor 4 (subtype EP4)
PTGER4
2.51

A_23_P345725
NM_014621
Homeobox D4
HOXD4
2.47

A_24_P125283
NM_001015053
Histone deacetylase 5
HDAC5
2.37

A_33_P3231953
NM_004370
Collagen, type XII, alpha 1
COL12A1
2.34

A_24_P298027
NM_004655
Axin 2
AXIN2
2.31

A_24_P336551
NM_199173
Bone gamma-carboxyglutamate (gla) protein
BGLAP
2.29

A_33_P3313825
XM_006713316
Transforming growth factor, beta receptor II (70/80 kDa)
TGFBR2
2.23

A_23_P82990
NM_033014
Osteoglycin
OGN
2.20

A_32_P24585
NM_001017995
SH3 and PX domains 2B
SH3PXD2B
2.20

A_24_P944458
NM_016133
Insulin induced gene 2
INSIG2
2.14

A_23_P99063
NM_002345
Lumican
LUM
2.12

A_32_P5251
NM_001024809
Retinoic acid receptor, alpha
RARA
2.11

A_24_P935491
NM_000090
Collagen, type III, alpha 1
COL3A1
2.10

A_33_P3312104
NM_025099
CTS telomere maintenance complex component 1
CTC1
2.06

A_33_P3321342
NM_016133
Insulin induced gene 2
INSIG2
2.04

A_23_P100486
NM_206824
Vitamin K epoxide reductase complex, subunit 1
VKORC1
2.02

A_23_P53588
NM_030775
Wingless-type MMTV integration site family, member 5B
WNT5B
2.00

A_23_P616356
NM_001291902
Low density lipoprotein receptor-related protein 5
LRP5
2.00

Table 2: Microarray data analysis showing genes related immune modulation and immune defense genes upregulated in CL2 versus CL1 cells.

ID
Gene name
Gene symbol
Fold change

A_23_P128094
ATP-binding cassette, subfamily B (MDR/TAP), member 9
ABCB9
2.1

A_32_P156963
Actin, gamma 1
ACTG1
3.0

A_23_P28279
ARP1 actin related protein 1 homolog B, centractin beta (yeast)
ACTR1B
2.0

A_23_P211207
Adenosine deaminase, RNA-specific, B1
ADARB1
3.5

A_23_P381261
Adenylate cyclase 4
ADCY4
5.0

A_23_P169993
Adenylate cyclase 8 (brain)
ADCY8
3.2

A_23_P76823
Adenylosuccinate synthase-like 1
ADSSL1
7.0

A_23_P135486
Alpha hemoglobin stabilizing protein
AHSP
2.6

A_23_P216023
Angiopoietin 1
ANGPT1
7.6

A_23_P94501
Annexin A1
ANXA1
2.6

A_23_P121716
Annexin A3
ANXA3
346.8

A_23_P6398
Adaptor-related protein complex 1, beta 1 subunit
AP1B1
2.2

A_23_P120931
Apolipoprotein B mRNA editing enzyme, catalytic polypeptide-like 3C
APOBEC3C
2.2

A_23_P132316
Apolipoprotein B mRNA editing enzyme, catalytic polypeptide-like 3D
APOBEC3D
2.4

A_23_P357101
Apolipoprotein B mRNA editing enzyme, catalytic polypeptide-like 3F
APOBEC3F
2.3

A_23_P143713
Apolipoprotein B mRNA editing enzyme, catalytic polypeptide-like 3G
APOBEC3G
9.6

A_23_P93988
Rho guanine nucleotide exchange factor (GEF) 5
ARHGEF5
8.7

A_24_P20383
Actin related protein 2/3 complex, subunit 4, 20 kDa
ARPC4
2.2

A_23_P208389
AXL receptor tyrosine kinase
AXL
2.0

A_33_P3279353
Azurocidin 1
AZU1
4.8

A_33_P3262043
BCL2-associated agonist of cell death
BAD
2.3

A_24_P159648
BAI1-associated protein 2
BAIAP2
2.2

A_23_P370682
Basic leucine zipper transcription factor, ATF-like 2
BATF2
22.2

A_23_P160720
Basic leucine zipper transcription factor, ATF-like 3
BATF3
3.0

A_33_P3229272
Breast cancer antiestrogen resistance 1
BCAR1
3.3

A_23_P210886
BCL2-like 1
BCL2L1
3.4

A_23_P98350
Baculoviral IAP repeat containing 3
BIRC3
25.0

A_23_P31725
B lymphoid tyrosine kinase
BLK
7.3

A_33_P3419785
BCL2/adenovirus E1B 19 kDa interacting protein 3
BNIP3
7.3

A_19_P00802936
BRICK1, SCAR/WAVE actin-nucleating complex subunit
BRK1
2.2

A_23_P2431
Complement component 3a receptor 1
C3AR1
2.6

A_23_P97541
Complement component 4 binding protein, alpha
C4BPA
2.6

A_23_P92928
Complement component 6
C6
4.0

A_23_P213857
Complement component 7
C7
2.2

A_33_P3745146
Cell adhesion molecule 1
CADM1
34.3

A_23_P250347
Calcium/calmodulin-dependent protein kinase IV
CAMK4
3.4

A_23_P253791
Cathelicidin antimicrobial peptide
CAMP
3.3

A_23_P82324
Caspase recruitment domain family, member 11
CARD11
7.9

A_23_P500433
Caspase recruitment domain family, member 9
CARD9
2.4

A_23_P202978
Caspase 1, apoptosis-related cysteine peptidase
CASP1
2.4

A_23_P123853
Chemokine (C-C motif) ligand 19
CCL19
2.0

A_23_P17065
Chemokine (C-C motif) ligand 20
CCL20
14.6

A_23_P215484
Chemokine (C-C motif) ligand 26
CCL26
2.8

A_23_P503072
Chemokine (C-C motif) ligand 28
CCL28
4.3

A_33_P3316273
Chemokine (C-C motif) ligand 3
CCL3
2.3

A_23_P152838
Chemokine (C-C motif) ligand 5
CCL5
2.7

A_23_P78037
Chemokine (C-C motif) ligand 7
CCL7
16.0

A_23_P207456
Chemokine (C-C motif) ligand 8
CCL8
2.8

A_23_P361773
Cyclin D3
CCND3
2.3

A_33_P3284508
CD14 molecule
CD14
4.2

A_23_P259863
CD177 molecule
CD177
2.7

A_33_P3381513
CD274 molecule
CD274
10.8

A_23_P15369
CD300 molecule-like family member b
CD300LB
2.0

A_23_P416747
CD3e molecule, epsilon (CD3-TCR complex)
CD3E
2.7

A_24_P188377
CD55 molecule, decay accelerating factor for complement (Cromer blood group)
CD55
5.9

A_23_P300056
Cell division cycle 42
CDC42
4.5

A_32_P148710
Cofilin 1 (nonmuscle)
CFL1
2.8

A_33_P3217584
Cholinergic receptor, nicotinic, alpha 4 (neuronal)
CHRNA4
2.9

A_33_P3415300
Complexin 2
CPLX2
2.7

A_23_P133408
Colony stimulating factor 2 (granulocyte-macrophage)
CSF2
16.5

A_33_P3396139
Cytotoxic T-lymphocyte-associated protein 4
CTLA4
3.0

A_33_P3287631
Cathepsin B
CTSB
2.3

A_33_P3283480
Cathepsin C
CTSC
8.2

A_23_P7144
Chemokine (C-X-C motif) ligand 1 (melanoma growth stimulating activity, alpha)
CXCL1
6.5

A_33_P3712341
Chemokine (C-X-C motif) ligand 12
CXCL12
4.8

A_33_P3351249
Chemokine (C-X-C motif) ligand 16
CXCL16
11.6

A_23_P315364
Chemokine (C-X-C motif) ligand 2
CXCL2
3.3

A_24_P183150
Chemokine (C-X-C motif) ligand 3
CXCL3
2.9

A_23_P155755
Chemokine (C-X-C motif) ligand 6
CXCL6
5.0

A_33_P3214550
Chemokine (C-X-C motif) receptor 2
CXCR2
2.0

A_33_P3389230
Chemokine (C-X-C motif) receptor 3
CXCR3
2.3

3.3. CL1 Cells Exhibit Enhanced Adipocyte Differentiation

We observed significant differences between CL1 and CL2 in their response to adipocytic differentiation induction. CL1 differentiated readily to adipocytes compared to CL2 (Figure 2(d), lower panel) evidenced by higher levels of adipocytic markers gene expression, LPL (lipoprotein lipase), and adiponectin, as well as formation of mature lipid filled adipocytes visualized by Oil Red-O staining and quantitative Nile red staining (Figure 2(d)).

3.4. CL1 Cells Differentiate to Chondrocytic Lineage

In pellet cultures, CL1 cells formed 3D pellets containing proteoglycan-secreting chondrocytes, which stained positive with Alcian blue. Limited chondrocyte differentiation was visible in cell pellets of CL2 cells. The differentiated chondrocytes in CL1 pellets expressed higher levels of collagen X and collagen II, which was overlapping the Alcian blue stain (Figure 2(e)).

3.5. Molecular Signature of CL1 and CL2 Cells

To define the molecular signature and molecular differences between CL1 and CL2, we compared the basal gene expression pattern of CL1 and CL2 cells using DNA microarrays. The PCA analysis showed a clear separation between CL1 and CL2 (Supplementary Figure ). Comparison between CL1 with CL2 showed that 915 genes were differentially expressed in the two cell lines (>2-fold, ): 462 genes were upregulated, and 452 were downregulated in CL1 versus CL2. The most relevant genes that were upregulated in CL1 are listed in Table 3(a). Among these 35 highly expressed genes in CL1, the following 11 genes were present in skeletal and muscular system development and function: FOLR3, CCL3L1, SERPINB2, POSTN, IGFBP5, CCL3, NOV, ALP, TNFRSF11B, ACTG2, and CDH11 (Table 3(a)). Functional annotation of the upregulated genes in CL1 using the Ingenuity Pathway Analysis (IPA) revealed enrichment in the following categories: “tissue development,” “skeletal and muscular system development and function,” and “organismal development” (Table 3(b)). Furthermore, the DAVID annotation tool was employed to assess the functional relationships of the upregulated genes in CL1 showing enrichment in ontologies: “skeletal and muscular system development and function” that included bone size, osteoblast differentiation, bone mineralization, and bone mineral density (Table 3(c)). CL1 exhibited upregulation of WNT pathway ligands: WNT5B (2-fold) and LRP5 (2-fold) (Table 1). Also, ALP was among the highly expressed genes together with POSTN, IGFBP5, SPP1, IL-6, and DKK1 (Tables 3(a) and 1). These genes are known to play an important role in osteoblast differentiation and bone formation. For CL2, inhibitors of WNT pathway were upregulated and included SFRP1 (11-fold), DKK2 (3.2-fold), FGF2 (3.1-fold), and GBP2 (2.4-fold). Functional annotation of the upregulated genes in CL2 revealed enrichment in the following categories: “developmental process,” “multicellular organismal process,” “biological adhesion,” and “immune system process” (Supplementary Table 2A). In-depth analysis of the biological processes revealed several immune-related pathways: “MAPKKK cascade,” “immunity and defense,” “signal transduction,” “extracellular matrix protein-mediated signaling,” and “interferon-mediated immunity,” among others that were upregulated (Supplementary Table 2B). Also, 40 genes related to immune system related factors were identified as significantly enriched in CL2 compared to CL1 cells (Supplementary Table 2C). We chose the following genes for validation of the microarray results: NOV, IGFBP5, ALP, TAGLN, and CDH11 as they were highly expressed in CL1. RT-PCR analysis confirmed the microarray results (Figure 3).

Table 3: Whole genome microarray analysis of two clonal populations of human bone marrow stromal stem cells: CL1 and CL2 cells. (a) Top 35 highly upregulated genes in CL1 cells versus CL2 cells. (b) Ingenuity® Pathway Analysis (IPA®) showing the different physiological system development and function genes found in each category and the corresponding value. (c) Upper part IPA analysis showing the categories for skeletal and muscular system development and function upregulated in CL1 cells and lower part showing genes upregulated in CL2 cells. NOV = nephroblastoma overexpressed, IGFBP5 = insulin-like growth factor binding protein 5, ALP, TAGLN = transgelin, and CDH11 = OB-cadherin (osteoblast).

(a)

Gene ID
Fold change CL1 versus CL2

FOLR3
28.4721

CCL3L3
17.936

POSTN
15.5924

SERPINB2
−17.2599

IGFBP5
14.6708

CCL3
13.1203

NOV
11.2921

ACTG2
10.4493

CRYAB
10.0678

PSG4
9.68913

RAB3IL1
9.16897

SCIN
9.13702

MYL9
9.12814

TNFRSF11B
8.86049

TAGLN
8.75581

CDH12
8.06682

SHISA2
8.0291

THBS1
7.86854

SPP1
7.64205

LCE2A
7.41042

TMEM98
7.38011

PSG7
7.12183

MYPN
7.01837

FNDC1
6.88102

TNS3
6.72083

ABI3BP
6.67822

LRP3
6.64307

MMP3
6.34715

FAM167A
6.02684

HSPB2
6.01063

ALPL
6.01022

CTSK
5.87356

CXCL12
5.68572

THY1
4.89445

CDH10
4.86105

(b)

Name
value
# molecules

Physiological system development and function

Organismal development

181

Embryonic development

154

Organ development

145

Skeletal and muscular system development and function

123

Tissue development

236

(c)

Functions annotation
value
# molecules

 Skeletal and muscular system development and  function upregulated in CL1 cells

Size of bone

24

Differentiation of osteoblasts

25

Mineralization of bone

19

Bone mineral density

19

 Skeletal and muscular system development and  function upregulated in CL2 cells

Development of muscle

44

Proliferation of muscle cells

35

Remodeling of bone

21

Resorption of bone

19

Figure 3: Validation of whole genome microarray analysis of two clonal populations of human bone marrow stromal stem cells: CL1 and CL2 cells. Quantitative real-time PCR for highly expressed genes in CL1 cells. NOV = nephroblastoma overexpressed, IGFBP5 = insulin-like growth factor binding protein 5, ALP, TAGLN = transgelin, and CDH11 = OB-cadherin (osteoblast). Data are presented as fold change in expression of each target gene normalized to GAPDH ( = three independent experiments, ) (see also Table 3).

Furthermore, we compared the molecular phenotype of CL1 and CL2 cells with that of phBMSC. We found that more than 80% of the genes expressed in CL1 and 90% in CL2 cells were common with primary phBMSC (Supplementary Figure ), suggesting that CL1 and CL2 molecular phenotype exist within the heterogeneous population of phBMSC cultures.

3.6. ALP Knockdown Impairs Differentiation of CL1 Cells

Since ALP has been suggested as a marker for hBMSC progenitor cell lineage commitment [13] and was highly upregulated in CL1 cells, we tested its biological role in CL1 cells. ALP siRNA transfection decreased ALP protein level, ALP activity, and mRNA gene expression compared to control cells transfected with control siRNA () and this inhibition was detectable up to day 7 days after osteoblast differentiation induction (Figures 4(A) and 4(B)). At day 14 of differentiation, mineralization ability of CL1 was significantly impaired (Figure 4(C)). In addition, we found that the number of mature adipocyte formations was significantly reduced to more than 75% () (Figure 4(D)).

Figure 4: Effect of alkaline phosphatase (ALP) gene silencing by small interfering RNA (siRNA) on a clonal population of human bone marrow stromal stem cell CL1. (A) ALP staining at day 3, day 5, or day 7 days of osteoblast differentiation (OB induction). (B) Quantitative real-time PCR for ALP gene following ALP siRNA transfection at day 0 OB and day 7 of OB. Data are presented as fold change in expression of each target gene normalized to GAPDH ( = three independent experiments, ). Western blotting analysis of day 3 and day 7 after siRNA ALP transfection of CL1 cells, ALPL specific antibody, and B-actin was used. (C) Mineralized matrix formation as visualized by Alizarin Red S staining in siRNA transfected CL1 cells after 14 days of OB induction. (D) Nile red quantification of mature lipid filled adipocyte in control noninduced (Cont), adipocyte induced (Adip I), and ALP siRNA transfected cells that are adipocyte induced (ALP siRNA). Adipocyte induction was carried out for 7 days. .

To identify relevant adipocyte differentiation associated genes that were targeted by ALP deficiency, we compared the downregulated genes of ALP deficient CL1 with the upregulated genes identified during adipocytic differentiation of CL1. We identified 62 genes that were common (Figure 5(a), Table 4) and among these genes were genes related to metabolism (primarily lipid and carbohydrate) and transport including CYB5B, CHST1, TAP1, ATP8A1, LRP8, PLCD1, and FABP5 (Table 4). We further performed quantitative real-time PCR of ALP deficient CL1 cells during adipocyte differentiation. The following adipocyte-associated genes were downregulated: PPARγ2, LPL, and aP2 (Figure 5(b)), confirming impairment of adipocytic differentiation of ALP deficient CL1 cells.

Table 4: Microarray data analysis showing genes found to be upregulated during adipogenic differentiation and downregulated after ALP KO.

62 common elements in “AD up” and “ALP down”
Gene name
FC (ALP siRNA versus control siRNA)

APOBEC3G
Apolipoprotein B mRNA editing enzyme, catalytic polypeptide-like 3G
−15.938025

IFI44L
Interferon-induced protein 44-like
−11.520283

PAQR5
Progestin and adipoQ receptor family member V
−6.868241

PNMA2
Paraneoplastic antigen MA2
−5.9695344

DUSP23
Dual specificity phosphatase 23
−5.4786854

CLDN23
Claudin 23
−5.1885047

ANKDD1A
Ankyrin repeat and death domain containing 1A
−5.1646647

IL8
Interleukin 8
−4.887188

LRRC23
Leucine rich repeat containing 23
−4.7611775

IL6
Interleukin 6 (interferon, beta 2)
−4.693139

LIFR
Leukemia inhibitory factor receptor alpha
−4.6540866

PTGFR
Prostaglandin F receptor (FP)
−4.457529

FAM134B
Family with sequence similarity 134, member B
−4.403495

CYFIP2
Cytoplasmic FMR1 interacting protein 2
−4.260462

METTL7A
Methyltransferase-like 7A
−4.0480843

APOBEC3F
Apolipoprotein B mRNA editing enzyme, catalytic polypeptide-like 3F
−3.9502614

CA5B
Carbonic anhydrase VB, mitochondrial
−3.93889

ITGA10
Integrin, alpha 10
−3.9143775

FMO3
Flavin containing monooxygenase 3
−3.852087

IMPA2
Inositol monophosphatase 2 (human)
−3.8374884

CDO1
Cysteine dioxygenase, type I
−3.8181455

CCDC68
Coiled-coil domain containing 68
−3.7292893

CXCL1
Chemokine (C-X-C motif) ligand 1 (melanoma growth stimulating activity, alpha)
−3.5942702

IDO1
Indoleamine 2,3-dioxygenase 1
−3.5803545

KCNIP3
Kv channel interacting protein 3, calsenilin
−3.5442894

FADS1
Fatty acid desaturase 1
−3.2951858

LSR
Lipolysis stimulated lipoprotein receptor
−3.2215986

ITGA7
Integrin, alpha 7
−3.1355932

HLA-DMA
Major histocompatibility complex, class II, DM alpha
−3.1347752

APOBEC3B
Apolipoprotein B mRNA editing enzyme, catalytic polypeptide-like 3B
−3.1074922

BMP4
Bone morphogenetic protein 4
−3.0809238

DMBT1
Deleted in malignant brain tumors 1
−3.0760298

RDH5
Retinol dehydrogenase 5 (11-cis/9-cis)
−3.066812

EPAS1
Endothelial PAS domain protein 1
−3.0615559

CDKN3
Cyclin-dependent kinase inhibitor 3
−3.052319

GPC6
Glypican 6
−3.0460389

CDK4
Cyclin-dependent kinase 4
−2.9808035

FKBP5
FK506 binding protein 5
−2.9360793

PDE1B
Phosphodiesterase 1B, calmodulin-dependent
−2.8863106

JAM2
Junctional adhesion molecule 2
−2.884354

TFPI
Tissue factor pathway inhibitor (lipoprotein-associated coagulation inhibitor)
−2.8578906

NT5M
5′,3′-Nucleotidase, mitochondrial
−2.7555947

NFIA
Nuclear factor I/A
−2.7176137

TSPAN31
Tetraspanin 31
−2.627556

ZNF25
Zinc finger protein 25
−2.6183622

SULF2
Sulfatase 2
−2.5464642

MESP1
Mesoderm posterior 1 homolog (mouse)
−2.525513

BCL2L1
BCL2-like 1
−2.5119667

PLTP
Phospholipid transfer protein
−2.4767148

TIMP4
TIMP metallopeptidase inhibitor 4
−2.465897

CYP27A1
Cytochrome P450, family 27, subfamily A, polypeptide 1
−2.4572072

TTC39B
Tetratricopeptide repeat domain 39B
−2.4439611

IL1R2
Interleukin 1 receptor, type II
−2.427431

FMOD
Fibromodulin
−2.4185398

LDLRAD3
Low density lipoprotein receptor class A domain containing 3
−2.4032724

PISD
Phosphatidylserine decarboxylase
−2.3884957

TMEM100
Transmembrane protein 100
−2.384632

CHST2
Carbohydrate (N-acetylglucosamine-6-O) sulfotransferase 2
−2.3805838

APOBEC3F
Apolipoprotein B mRNA editing enzyme, catalytic polypeptide-like 3F
−2.3759322

SCD
Stearoyl-CoA desaturase (delta-9-desaturase)
−2.3524246

SPAG4
Sperm associated antigen 4
−2.280867

MMD
Monocyte to macrophage differentiation associated human
−2.2055967

ASS1
Argininosuccinate synthase 1
−2.1725202

GK5
Glycerol kinase 5 (putative)
−2.1667244

PDE7B
Phosphodiesterase 7B
−2.166515

MT1X
Metallothionein 1X
−2.161843

ACACB
Acetyl-CoA carboxylase beta
−2.1512873

LEPR
Leptin receptor
−2.148686

HIF1A
Hypoxia inducible factor 1, alpha subunit (basic helix-loop-helix transcription factor)
−2.0954225

HEXDC
Hexosaminidase (glycosyl hydrolase family 20, catalytic domain) containing
−2.094836

SARM1
Sterile alpha and TIR motif containing 1
−2.0797038

BBS1
Bardet-Biedl syndrome 1
−2.0146718

SERPING1
Serpin peptidase inhibitor, clade G (C1 inhibitor), member 1
−2.0102212

FAM162A
Family with sequence similarity 162, member A
−2.005807

TCTN1
Tectonic family member 1
−2.0033443

(a)

(b)

Figure 5: Adipocyte related genes downregulated in ALP knockdown CL1 cells. (a) Venn diagram of whole gene expression analysis of AD upregulated genes compared with ALP KD downregulated genes. (b) Quantitative real-time PCR of four selected common genes from Venn diagram including ALPL, PPARg2, aP2, and LPL. Data are presented as fold change in expression of each target gene normalized to GAPDH ( = three independent experiments, , , and ).

4. Discussion

We extensively studied two cell populations within cultured hBMSC that were identified based on differences in morphology. Cellular and molecular studies revealed differences in growth, differentiation capacity, and molecular signature. Our data support the notion of the presence of cellular and functional heterogeneity among cultured hBMSC.

Cellular heterogeneity of cultured hBMSC is recognized in an increasing number of reports. Several extrinsic and intrinsic factors may contribute to the observed hBMSC heterogeneity. Extrinsic factors include donor-to-donor variations in the number and quantity of initiating cells, which result in differences in cell growth rate and differentiation capacity [14, 15]. Intrinsic factors have been examined employing single cell clonal analysis and revealed variations in differentiation potential among individual colonies within hBMSC cultures ranging from the presence of cells with trilineage (osteoblast, adipocytes, and chondrocyte) potency to cells with null potency [16]. Also, variations in the ability of clonal cells to form heterotopic bone when implanted in vivo have been reported [5]. Our study corroborates these findings and provides more detailed cellular and molecular phenotyping of two examples of cell populations that exist within the heterogeneous hBMSC cultures [17].

Determining the molecular signature of CL1 and CL2 using whole genome microarray analysis showed enrichment of lineage-commitment associated genes in CL1. For example, insulin-like growth factor 5 (IGFBP5) and interleukin 6 (IL6) were 14.7- and 3.3-fold upregulated in CL1 cells, respectively. Both factors are expressed in osteoprogenitor cells and important for osteoblast maturation [18]. We also observed that periostin (POSTN) gene was highly upregulated in CL1 cells (15.6-fold); POSTN is a 90 kDa secreted protein, originally identified in murine osteoblast-like cells and is upregulated by PTH [19]. Several studies employing murine and human cells have revealed important role of POSTN in osteoblast differentiation and during development in intramembranous ossification [20–23]. Another factor identified in CL1 cells is nephroblastoma overexpression (NOV) which is a member of the Cyr 61, connective tissue growth factor (CNN) family. The CCN family of proteins promotes osteoblast differentiation through interaction with integrins, WNT, BMP, and NOTCH signaling pathways [24–26]. In addition, a large number of signaling molecules known to be regulators of hBMSC lineage specific differentiation, for example, insulin-like growth factors [27–29], WNT [30–32], and MAPK [33–35], were enriched in CL1 cells. In contrast, CL2 expressed high levels of immune-related genes which may explain the poor differentiation response to osteoblast or adipocyte lineage. In a recent study the authors used telomerized hBMSC and showed clearly a clonal population that had very low in vitro and in vivo differentiation ability; however they had enhanced immune-related features including high IL7 expression. These nullipotent cells expressed CD317 which was associated with remarkably high basal level expression of factors with a proinflammatory and antiviral function [17]. We observed that this molecular phenotype was associated with distinct ultrastructural characteristics of the cells. In particular, CL2 had abundant phagocytic vacuole, microvilli, and lysosomes, features reminiscent of ultrastructure of immune-regulatory cells. Our data thus support the increasingly recognized feature that hBMSC exhibit immune modulatory functions and a part of the innate immune response [17].

We observed that ALP protein expression and enzymatic activity were significantly different between CL1 and CL2 cell lines and were thus a potential marker that distinguishes different cell populations with progenitor functions (CL1) from cells with nonprogenitor functions (CL2). ALP is expressed in a wide variety of tissues, including kidneys, bone, and liver [36, 37], but tissue-nonspecific ALP (ALPL) is considered a commitment marker for osteoblastic lineage [13, 38]. However, in a recent study the authors examined the differentiation potential of a number of hMSC clones in vitro and in vivo and reported that the hMSC clones with high levels of ALP expression were committed to trilineage differentiation [13]. Our data corroborate and extend these findings by reporting the effects of siRNA-mediated inhibition of ALP that resulted in an impaired hBMSC differentiation not only to osteoblasts, but also to adipocytes. Also, our results corroborate earlier studies that demonstrated in human bone biopsies the presence of ALP expression in bone marrow adipocytic cells [13, 17]. All these data suggest that ALP is a “stemness” marker of hBMSC and not just an indicator of osteoblastic lineage commitment.

While CL1 and CL2 were isolated from telomerized hMSC cell line, they are relevant to normal human physiology. We observed that the molecular phenotypes of CL1 and CL2 were contained within the molecular signature of primary hBMSC suggesting that CL1 and CL2 represent cell populations within the heterogeneous cultures of hBMSC. We have also previously reported that the molecular phenotype and cellular responses of hMSC-TERT are similar to those of primary hMSC [10]. While we have identified ALP as a marker that can be used for a prospective identification of differentiation committed population of hBMSC, we identified additional distinctive molecular markers of the cells. For example, IGF-1, IGF-2, and IGF binding protein 5 were enriched in CL1 compared to CL2. IGFs and their binding proteins are very well-studied factors that play a role in hBMSC proliferation and osteoblast differentiation [18]. On the other hand, annexin A3 as well as several immune-related genes was highly enriched in CL2 compared to CL1. Future studies are needed to determine the functional significance of these molecules in relation to the functional identity of various cell populations within the hBMSC cultures and their usefulness as biomarkers to dissect the heterogeneous population of cultured hBMSC.

Our finding of the presence of functional diversity within hBMSC cultures that contain progenitor and nonprogenitor cell populations has a clinical relevance. It demonstrates that the progenitor function and the immune modulatory roles of hBMSC [39] are mediated by specific and distinguishable populations of hBMSC. Thus, future clinical studies employing hBMSC should attempt to administer the relevant subpopulation of hBMSC dependent on the experimental aim, as a novel approach to improving the clinical efficiency, instead of the current use of heterogeneous hBMSC populations.

Competing Interests

The authors declare that they have no competing interests.

Authors’ Contributions

Mona Elsafadi and Amer Mahmood contributed equally to this work.

Acknowledgments

These studies are supported by a grant from the College of Medicine Research Centre (CMRC), Deanship of Scientific Research, King Saud University, Riyadh, Saudi Arabia. The authors would like to thank Mr. Ali Al-Roalle for all his technical help. They thank Natalie Twine for advice on DNA microarray analysis.

References

W. Zaher, L. Harkness, A. Jafari, and M. Kassem, “An update of human mesenchymal stem cell biology and their clinical uses,” Archives of Toxicology, vol. 88, no. 5, pp. 1069–1082, 2014.

S. Post, B. M. Abdallah, J. F. Bentzon, and M. Kassem, “Demonstration of the presence of independent pre-osteoblastic and pre-adipocytic cell populations in bone marrow-derived mesenchymal stem cells,” Bone, vol. 43, no. 1, pp. 32–39, 2008.

K. H. Larsen, C. M. Frederiksen, J. S. Burns, B. M. Abdallah, and M. Kassem, “Identifying a molecular phenotype for bone marrow stromal cells with in vivo bone-forming capacity,” Journal of Bone and Mineral Research, vol. 25, no. 4, pp. 796–808, 2010.

A. Rosenzweig, “Cardiac cell therapy—mixed results from mixed cells,” The New England Journal of Medicine, vol. 355, no. 12, pp. 1274–1277, 2006.

S. A. Kuznetsov, P. H. Krebsbach, K. Satomura et al., “Single-colony derived strains of human marrow stromal fibroblasts form bone after transplantation in vivo,” Journal of Bone and Mineral Research, vol. 12, no. 9, pp. 1335–1347, 1997.

M. Kassem and P. Bianco, “Skeletal stem cells in space and time,” Cell, vol. 160, no. 1-2, pp. 17–19, 2015.

A. I. Caplan and D. Correa, “PDGF in bone formation and regeneration: new insights into a novel mechanism involving MSCs,” Journal of Orthopaedic Research, vol. 29, no. 12, pp. 1795–1803, 2011.

K. Stewart, S. Walsh, J. Screen et al., “Further characterization of cells expressing STRO-1 in cultures of adult human bone marrow stromal cells,” Journal of Bone and Mineral Research, vol. 14, no. 8, pp. 1345–1356, 1999.

J. L. Simonsen, C. Rosada, N. Serakinci et al., “Telomerase expression extends the proliferative life-span and maintains the osteogenic potential of human bone marrow stromal cells,” Nature Biotechnology, vol. 20, no. 6, pp. 592–596, 2002.

M. Al-Nbaheen, R. Vishnubalaji, D. Ali et al., “Human stromal (mesenchymal) stem cells from bone marrow, adipose tissue and skin exhibit differences in molecular phenotype and differentiation potential,” Stem Cell Reviews and Reports, vol. 9, no. 1, pp. 32–43, 2013.

C. A. Gregory, W. G. Gunn, A. Peister, and D. J. Prockop, “An Alizarin red-based assay of mineralization by adherent cells in culture: comparison with cetylpyridinium chloride extraction,” Analytical Biochemistry, vol. 329, no. 1, pp. 77–84, 2004.

A. Mahmood, L. Harkness, H. D. Schrøder, B. M. Abdallah, and M. Kassem, “Enhanced differentiation of human embryonic stem cells to mesenchymal progenitors by inhibition of TGF-β/activin/nodal signaling using SB-431542,” Journal of Bone and Mineral Research, vol. 25, no. 6, pp. 1216–1233, 2010.

H.-J. Prins, A. K. Braat, D. Gawlitta et al., “In vitro induction of alkaline phosphatase levels predicts in vivo bone forming capacity of human bone marrow stromal cells,” Stem Cell Research, vol. 12, no. 2, pp. 428–440, 2014.

K. Stenderup, J. Justesen, C. Clausen, and M. Kassem, “Aging is associated with decreased maximal life span and accelerated senescence of bone marrow stromal cells,” Bone, vol. 33, no. 6, pp. 919–926, 2003.

D. G. Phinney, G. Kopen, W. Righter, S. Webster, N. Tremain, and D. J. Prockop, “Donor variation in the growth properties and osteogenic potential of human marrow stromal cells,” Journal of Cellular Biochemistry, vol. 75, no. 3, pp. 424–436, 1999.

C. M. Digirolamo, D. Stokes, D. Colter, D. G. Phinney, R. Class, and D. J. Prockop, “Propagation and senescence of human marrow stromal cells in culture: a simple colony-forming assay identifies samples with the greatest potential to propagate and differentiate,” British Journal of Haematology, vol. 107, no. 2, pp. 275–281, 1999.

S. James, J. Fox, F. Afsari et al., “Multiparameter analysis of human bone marrow stromal cells identifies distinct immunomodulatory and differentiation-competent subtypes,” Stem Cell Reports, vol. 4, no. 6, pp. 1004–1015, 2015.

B. Peruzzi, A. Cappariello, A. Del Fattore, N. Rucci, F. De Benedetti, and A. Teti, “c-Src and IL-6 inhibit osteoblast differentiation and integrate IGFBP5 signalling,” Nature Communications, vol. 3, article 630, 2012.

D. Fortunati, S. Reppe, Å.-K. Fjeldheim, M. Nielsen, V. T. Gautvik, and K. M. Gautvik, “Periostin is a collagen associated bone matrix protein regulated by parathyroid hormone,” Matrix Biology, vol. 29, no. 7, pp. 594–601, 2010.

A. Oshima, H. Tanabe, T. Yan, G. N. Lowe, C. A. Glackin, and A. Kudo, “A novel mechanism for the regulation of osteoblast differentiation: transcription of periostin, a member of the fasciclin I family, is regulated by the bHLH transcription factor, Twist,” Journal of Cellular Biochemistry, vol. 86, no. 4, pp. 792–804, 2002.

T. G. Kashima, T. Nishiyama, K. Shimazu et al., “Periostin, a novel marker of intramembranous ossification, is expressed in fibrous dysplasia and in c-Fos-overexpressing bone lesions,” Human Pathology, vol. 40, no. 2, pp. 226–237, 2009.

C. Galli, M. Piergianni, M. Piemontese et al., “Periostin improves cell adhesion to implantable biomaterials and osteoblastic differentiation on implant titanium surfaces in a topography-dependent fashion,” Journal of Biomedical Materials Research - Part A, vol. 102, no. 11, pp. 3855–3861, 2014.

D. L. Coutu, H. W. Jian, A. Monette, G.-É. Rivard, M. D. Blostein, and J. Galipeau, “Periostin, a member of a novel family of vitamin K-dependent proteins, is expressed by mesenchymal stromal cells,” The Journal of Biological Chemistry, vol. 283, no. 26, pp. 17991–18001, 2008.

T. Minamizato, K. Sakamoto, T. Liu et al., “CCN3/NOV inhibits BMP-2-induced osteoblast differentiation by interacting with BMP and Notch signaling pathways,” Biochemical and Biophysical Research Communications, vol. 354, no. 2, pp. 567–573, 2007.

W. Si, Q. Kang, H. H. Luu et al., “CCN1/Cyr61 is regulated by the canonical Wnt signal and plays an important role in Wnt3A-induced osteoblast differentiation of mesenchymal stem cells,” Molecular and Cellular Biology, vol. 26, no. 8, pp. 2955–2964, 2006.

Q. Luo, Q. Kang, W. Si et al., “Connective tissue growth factor (CTGF) is regulated by Wnt and bone morphogenetic proteins signaling in osteoblast differentiation of mesenchymal stem cells,” The Journal of Biological Chemistry, vol. 279, no. 53, pp. 55958–55968, 2004.

Y.-S. Yoon, N. Lee, and H. Scadova, “Myocardial regeneration with bone-marrow-derived stem cells,” Biology of the Cell, vol. 97, no. 4, pp. 253–263, 2005.

Y. S. Yoon, “Cardiac regeneration with novel bone marrow-derived multipotent stem cells,” Discovery Medicine, vol. 5, pp. 204–208, 2005.

Y.-S. Yoon, A. Wecker, L. Heyd et al., “Clonally expanded novel multipotent stem cells from human bone marrow regenerate myocardium after myocardial infarction,” Journal of Clinical Investigation, vol. 115, no. 2, pp. 326–338, 2005.

G. M. Boland, G. Perkins, D. J. Hall, and R. S. Tuan, “Wnt 3a promotes proliferation and suppresses osteogenic differentiation of adult human mesenchymal stem cells,” Journal of Cellular Biochemistry, vol. 93, no. 6, pp. 1210–1230, 2004.

D. A. Cook, S. W. Fellgett, M. E. Pownall, P. J. O'Shea, and P. G. Genever, “Wnt-dependent osteogenic commitment of bone marrow stromal cells using a novel GSK3β inhibitor,” Stem Cell Research, vol. 12, no. 2, pp. 415–427, 2014.

J. De Boer, R. Siddappa, C. Gaspar, A. Van Apeldoorn, R. Fodde, and C. Van Blitterswijk, “Wnt signaling inhibits osteogenic differentiation of human mesenchymal stem cells,” Bone, vol. 34, no. 5, pp. 818–826, 2004.

M. Al-Toub, A. Almusa, M. Almajed et al., “Pleiotropic effects of cancer cells' secreted factors on human stromal (mesenchymal) stem cells,” Stem Cell Research and Therapy, vol. 4, article 114, 2013.

L. Chen, D. Qanie, A. Jafari et al., “Delta-like 1/fetal antigen-1 (Dlk1/FA1) is a novel regulator of chondrogenic cell differentiation via inhibition of the Akt kinase-dependent pathway,” The Journal of Biological Chemistry, vol. 286, no. 37, pp. 32140–32149, 2011.

T. Matsunobu, K. Torigoe, M. Ishikawa et al., “Critical roles of the TGF-β type I receptor ALK5 in perichondrial formation and function, cartilage integrity, and osteoblast differentiation during growth plate development,” Developmental Biology, vol. 332, no. 2, pp. 325–338, 2009.

B. C. Nair, D. E. Johnson, R. J. Majeska, J. A. Rodkey, C. D. Bennett, and G. A. Rodan, “Rat alkaline phosphatase. II. Structural similarities between the osteosarcoma, bone, kidney, and placenta isoenzymes,” Archives of Biochemistry and Biophysics, vol. 254, no. 1, pp. 28–34, 1987.

P. J. Butterworth, “Alkaline phosphatase. Biochemistry of mammalian alkaline phosphatases,” Cell Biochemistry and Function, vol. 1, no. 2, pp. 66–70, 1983.

A. T. Ali, C. B. Penny, J. E. Paiker et al., “Alkaline phosphatase is involved in the control of adipogenesis in the murine preadipocyte cell line, 3T3-L1,” Clinica Chimica Acta, vol. 354, no. 1-2, pp. 101–109, 2005.

G. M. Spaggiari and L. Moretta, “Cellular and molecular interactions of mesenchymal stem cells in innate immunity,” Immunology and Cell Biology, vol. 91, no. 1, pp. 27–31, 2012.